Ticino Artificial InTelligence integrAtioN for Occlusion Myocardial Infarction

Launched by CARDIOCENTRO TICINO · Jul 11, 2025

Keywords

ClinConnect Summary

This clinical trial is studying whether using an artificial intelligence (AI) tool to read heart tests (ECGs) can help doctors find and treat a type of heart attack called occlusion myocardial infarction (OMI) more quickly. This type of heart attack can be hard to spot with standard tests because it doesn’t always show the usual signs doctors look for. The trial will compare the AI tool to regular care to see if it helps start treatment earlier and reduces heart damage.

People who might join are adults 18 years or older who come to the hospital with symptoms like chest pain, shortness of breath, sweating, or nausea that suggest a possible heart problem, but who do not have clear signs of a typical heart attack on their ECG. Participants will be randomly assigned to have their ECG interpreted either with the help of the AI tool or by the usual method. They will then be followed up to see how quickly they receive treatment and how their heart is doing after 30 days. This study is not yet open for enrollment.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Symptoms suspected of ongoing acute myocardial ischemia: Patients presenting with symptoms such as chest pain, dyspnoea, sweating, nausea or vomiting, pain radiating to the shoulder/arm/jaw/back, fatigue, or light-headedness
• • 2. Age: Patients aged 18 years or older.
• • 3. Informed Consent: Patients able to provide informed consent
• Exclusion Criteria:
• • 1. Clear diagnosis of ST-segment elevation MI (STEMI) according to managing physicians.
• • 2. Pregnancy or Lactation.
• • 3. Legally incompetent to provide informed consent.
• • 4. Symptoms onset\>24 hrs prior to clinical presentation.